-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-01-11
1AE:F:F-Argen-X (EUR)
COMMON STOCK | Biotechnology |
Last Closing
USD 647.6Change
0.00 (0.00)%Market Cap
USD 36.18BVolume
7.00Analyst Target
N/AVerdict
Verdict
Values as of: 2025-01-11
COMMON STOCK | Biotechnology |
Last Closing
USD 647.6Change
0.00 (0.00)%Market Cap
USD 36.18BVolume
7.00Analyst Target
N/AVerdict
Verdict
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Company Website : https://www.argenx.com
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
CSJ:F | CSL Limited |
N/A |
USD 82.25B |
CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 80.95B |
RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 74.41B |
1AEA:F | argenx SE |
N/A |
USD 36.18B |
UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 35.06B |
DUL:F | Alnylam Pharmaceuticals Inc |
N/A |
USD 29.18B |
22UA:F | BioNTech SE |
N/A |
USD 26.21B |
49B:F | BeiGene Ltd. |
N/A |
USD 20.08B |
49BA:F | BeiGene Ltd |
N/A |
USD 18.99B |
0QF:F | Moderna Inc |
N/A |
USD 14.82B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 7.79% | 77% | C+ | 86% | B+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 7.79% | 77% | C+ | 86% | B+ | ||
Trailing 12 Months | |||||||
Capital Gain | 86.52% | 87% | B+ | 94% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 86.52% | 87% | B+ | 86% | B+ | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 15.97% | 74% | C | 76% | C+ | ||
Dividend Return | 15.97% | 74% | C | 69% | C- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 18.51% | 91% | A- | 71% | C- | ||
Risk Adjusted Return | 86.29% | 99% | N/A | 89% | A- | ||
Market Capitalization | 36.18B | 99% | N/A | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector